What are the newest RPM technologies?

This blog post has been written by the person who has mapped the Remote Patient Monitoring market in a clean and beautiful presentation

The Remote Patient Monitoring (RPM) industry is experiencing explosive growth, with the global market projected to reach $56.94 billion by 2030, representing a robust 12.7% CAGR from 2024.

Five distinct technology categories are emerging as game-changers, targeting everything from acute hospital-at-home care to chronic disease management, while AI-driven platforms are reducing false alerts by 85% and improving patient outcomes significantly. And if you need to understand this market in 30 minutes with the latest information, you can download our quick market pitch.

What are the key categories of Remote Patient Monitoring technologies currently emerging in 2025?

Five distinct RPM technology categories are reshaping healthcare delivery, each targeting different risk levels and care settings with specific value propositions.

Hospital-at-Home RPM represents the highest-acuity category, supporting patients with conditions like sepsis, pneumonia, and post-surgical recovery through continuous multi-parameter monitoring. These systems typically combine wearable sensors, cellular connectivity, and 24/7 clinical monitoring teams to deliver inpatient-level care at home.

Chronic Disease Management RPM dominates market share, focusing on heart failure, diabetes, hypertension, and COPD monitoring. This segment leverages AI-powered predictive analytics to detect early deterioration patterns and prevent costly readmissions. Advanced glucose monitoring devices like Dexcom's CGM systems saw 31% growth in global shipments during 2023.

AI-Enhanced RPM Platforms represent the fastest-growing category, with the AI-in-RPM market projected to reach $8.44 billion by 2030 at a 27.5% CAGR. These platforms reduce false-positive alerts by up to 85% through machine learning algorithms that analyze patient-specific patterns and historical data trends.

Post-Acute Recovery RPM bridges the gap between hospital discharge and full recovery, monitoring patients during rehabilitation phases. This category specifically targets the 30-day readmission window that affects hospital reimbursement rates under CMS quality programs.

Which specific health conditions and patient populations are these new RPM technologies targeting?

RPM technologies in 2025 target six primary clinical domains, each addressing specific pain points that drive significant healthcare costs and patient outcomes challenges.

Cardiovascular conditions represent the largest target population, with heart failure affecting over 6.2 million Americans. Implicity's universal cardiac monitoring platform has raised $50.5 million to address the fragmented landscape of pacemaker and defibrillator monitoring across different device manufacturers. Their AI-driven alerts help prevent the 30% of heart failure patients who are readmitted within 30 days of discharge.

Diabetes management focuses on the 37.3 million Americans with diabetes, where continuous glucose monitoring prevents the $13,000 average annual healthcare cost per patient. Advanced RPM platforms now integrate CGM data with insulin pump adjustments and lifestyle coaching to optimize glycemic control automatically.

Maternal health RPM targets the 700+ maternal deaths annually in the US, with platforms like Babyscripts monitoring blood pressure, weight, and fetal heart rate remotely. This addresses the challenge that 60% of pregnancy-related deaths occur postpartum, often due to undetected complications like preeclampsia.

Oncology RPM serves the 2 million annual cancer diagnoses, focusing on chemotherapy monitoring and early infection detection. At-home blood count monitoring through devices like Entia's Liberty platform eliminates the need for frequent clinic visits while maintaining safety protocols.

Need a clear, elegant overview of a market? Browse our structured slide decks for a quick, visual deep dive.

If you want useful data about this market, you can download our latest market pitch deck here

Which startups and companies are leading innovation in the RPM space?

Seven key innovators are defining the RPM landscape through breakthrough technologies and significant funding rounds, each targeting specific market segments with proprietary platforms.

BioIntelliSense leads with FDA-cleared continuous monitoring devices that capture multi-parameter vital signs through skin-adherent sensors, serving major health systems like Houston Methodist and Renown Health. Their rechargeable BioButton received FDA clearance in October 2024 for multi-patient use, addressing hospital workflow efficiency.

What were the most significant RPM breakthroughs and product launches in the past 12 months?

Eight major product launches and regulatory clearances in 2024-2025 have expanded RPM capabilities into new clinical areas and improved existing platform performance.

Medtronic's MyCareLink Smart Monitor became the world's first app-based remote monitoring system for pacemaker patients, receiving FDA approval in January 2025. This breakthrough eliminates the need for dedicated bedside monitoring devices, using smartphones for data transmission and patient interaction.

BioIntelliSense achieved FDA clearance for their rechargeable BioButton and BioDashboard system in October 2024, enabling continuous patient monitoring across multiple hospital units. The system supports 60-day monitoring periods and integrates with existing hospital workflows through Epic and Cerner EHR systems.

Entia's Liberty at-home blood testing device received CE marking for European markets, enabling oncology patients to perform full blood counts from home using capillary blood samples. This addresses the challenge of frequent lab visits during chemotherapy treatment cycles.

CMS expanded RPM reimbursement for Federally Qualified Health Centers (FQHCs) and Rural Health Clinics (RHCs) through the new G0511 billing code, effective January 2024. This change enables previously underserved providers to offer RPM services while receiving separate reimbursement outside their all-inclusive rate structure.

Wondering who's shaping this fast-moving industry? Our slides map out the top players and challengers in seconds.

What percentage of patients and providers are actively using the latest RPM solutions?

RPM adoption has accelerated dramatically across all stakeholder groups, with provider adoption increasing over 300% since 2021 and patient utilization reaching critical mass thresholds.

Hospital RPM adoption jumped from 6% in 2019 to 34% by 2022, while physician practice utilization now reaches approximately 40% with 70% of those practices reporting improved patient engagement and revenue generation. This represents a fundamental shift from pilot programs to operational integration within clinical workflows.

By 2025, over 71 million Americans (26% of the adult population) are expected to use some form of RPM service, with highest adoption rates among patients aged 60 and older. This demographic alignment matches the highest healthcare utilization patterns and chronic disease prevalence.

Internal medicine physicians manage approximately 29% of all RPM patients, followed by cardiology at 21% and family practice providers handling the remainder. This distribution reflects the chronic disease focus of current RPM implementations and reimbursement structures.

Provider satisfaction metrics show 89% of patients agreeing that RPM helped them feel comfortable managing conditions at home, while 93% would recommend RPM to others with similar conditions. These engagement levels support the sustainability of RPM program expansion and patient retention.

Which RPM technologies have received recent funding and how much capital has been raised?

RPM funding in 2024-2025 totaled over $500 million across Series B and C rounds, with AI-powered platforms commanding the highest valuations and growth investments.

BioIntelliSense completed an $82 million funding series through July 2021, with their latest $45 million Series B led by Chimera (UAE) and including participation from 7wire Technology Partners, Philips, and Fresenius Medical Care. The company's medical-grade wearable platform serves both hospital systems and home monitoring applications.

Implicity raised $50.5 million across three funding rounds to develop their universal cardiac device monitoring platform. Their investor base includes European Innovation Council, BNP Paribas Développement, and EIT Health, reflecting strong European market validation.

DrKumo secured $60 million in growth funding to expand their real-time RPM SaaS platform, focusing on hospital-at-home and post-acute care applications. Their AI-powered triage system processes patient data in real-time to prioritize clinical interventions.

Athelas raised $132 million to advance at-home blood testing capabilities, combining rapid diagnostic devices with AI-powered result interpretation. Their platform addresses the challenge of frequent lab monitoring for chronic conditions and medication management.

Looking for the latest market trends? We break them down in sharp, digestible presentations you can skim or share.

If you need to-the-point data on this market, you can download our latest market pitch deck here

What regulatory clearances have the newest RPM solutions obtained?

FDA 510(k) clearances and CE markings have accelerated in 2024-2025, with twelve major RPM platforms receiving regulatory approval for clinical use across different monitoring applications.

BioIntelliSense received FDA clearance for both their single-use BioSticker and rechargeable BioButton devices, along with their BioDashboard analytics platform. These clearances enable continuous monitoring for up to 30-60 days with medical-grade accuracy for vital signs including heart rate, respiratory rate, and skin temperature.

Athelas achieved FDA clearance for their at-home blood testing devices, enabling rapid analysis of complete blood counts, lipid panels, and HbA1c testing from capillary blood samples. This clearance addresses the challenge of frequent lab monitoring for diabetes and cardiovascular patients.

Masimo's SafetyNet platform received CE marking for European deployment, focusing on hospital-at-home monitoring with continuous pulse oximetry and early warning score calculations. Their system integrates with existing hospital command centers for 24/7 clinical oversight.

Remaining regulatory hurdles include post-market surveillance requirements, data privacy compliance across different jurisdictions, and interoperability standards for EHR integration. The lack of standardization in RPM devices creates challenges for healthcare systems trying to integrate multiple vendor solutions.

How far along are these technologies in terms of development phase?

RPM technologies span the full development spectrum from early pilots to commercial scaling, with most established platforms now transitioning from clinical validation to operational deployment.

Pilot Phase technologies include ambient sensing solutions using LiDAR and computer vision for contactless vital sign monitoring. These systems are being tested in skilled nursing facilities and intensive care units but require additional clinical validation before widespread deployment.

Clinical Validation Phase includes AI-powered alert systems for specific chronic conditions like COPD exacerbation prediction and heart failure decompensation. Current algorithms can reduce false-positive alerts by up to 85% compared to traditional threshold-based monitoring.

Early Commercial Phase encompasses companies like HealthSnap, Implicity, and Babyscripts, which have moved beyond pilots to serve multiple health systems and payer organizations. These platforms typically serve 10,000-50,000 patients across regional healthcare networks.

Scaling Phase includes BioIntelliSense and Athelas, which are expanding internationally and serving major health systems with hundreds of thousands of monitored patients. These companies focus on operational efficiency, integration capabilities, and outcome validation at population scale.

What integration and interoperability issues still limit RPM adoption?

Four critical integration barriers continue to impede widespread RPM deployment, despite significant technological advances in device capabilities and clinical outcomes validation.

The lack of standardization across RPM devices creates significant challenges for healthcare systems, as different vendors use proprietary data formats and communication protocols. This forces hospitals to maintain multiple monitoring platforms or limit vendor choices to ensure compatibility.

EHR integration remains problematic due to limited FHIR support in legacy systems and inconsistent API implementations across major vendors like Epic, Cerner, and Allscripts. Many RPM platforms require manual data entry or custom integration work that costs $50,000-200,000 per health system implementation.

Proprietary device SDKs create vendor lock-in situations where healthcare providers cannot easily switch RPM platforms or integrate multiple solutions. This limits competitive pricing and innovation adoption, particularly for large health systems serving diverse patient populations.

Reimbursement complexity varies significantly across payers, with different coding requirements for Medicare, Medicaid, and private insurers. While CMS has standardized five RPM CPT codes (99453, 99454, 99457, 99458, and 99091), implementation varies across Medicare Administrative Contractors and regional payers.

Planning your next move in this new space? Start with a clean visual breakdown of market size, models, and momentum.

If you want to build or invest on this market, you can download our latest market pitch deck here

What market shifts are expected in 2026 that could accelerate RPM adoption?

Six major market shifts are converging in 2026 to create significant acceleration opportunities for RPM adoption across different healthcare settings and patient populations.

Closed-loop therapeutic RPM represents the next evolution, where monitoring devices automatically adjust treatment parameters based on real-time data. Examples include continuous glucose monitors that automatically adjust insulin pump delivery and blood pressure monitors that trigger medication dose modifications through physician-approved protocols.

CMS expansion of audio-only reimbursement and Advanced Primary Care Management (APCM) integration will enable broader RPM deployment in primary care settings. APCM combines chronic care management, virtual check-ins, and RPM services into coordinated care packages with enhanced reimbursement rates.

AI-powered personalized triage systems will mature from experimental to operational status, enabling healthcare systems to monitor thousands of patients simultaneously while reducing clinical workload. These systems prioritize interventions based on individual patient risk profiles and historical patterns.

Telehealth-RPM convergence will create unified platforms where virtual consultations automatically incorporate real-time and historical monitoring data. This integration eliminates the current disconnect between episodic telehealth visits and continuous monitoring insights.

Value-based care contracts will increasingly require RPM deployment as healthcare systems take on financial risk for patient outcomes. This shift makes RPM a strategic necessity rather than an optional technology enhancement.

What is the projected market size and growth forecast for different RPM segments?

RPM market projections show robust growth across all segments, with AI-enhanced platforms and chronic disease management leading expansion through 2030.

The global RPM market, valued at $27.72 billion in 2024, is projected to reach $56.94 billion by 2030, representing a 12.7% CAGR during the forecast period. The US market specifically is expected to grow from $14.15 billion in 2024 to $29.13 billion by 2030 at a 12.8% CAGR.

The AI-in-RPM segment represents the fastest growth opportunity, projected to expand from $1.97 billion in 2024 to $8.44 billion by 2030 at a 27.5% CAGR. This growth is driven by machine learning algorithms that improve clinical decision-making and reduce false alerts.

The European RPM market is expected to grow from $1.36 billion in 2025 to $3.17 billion by 2030 at an 18.42% CAGR, driven by aging populations and government digital health initiatives across major European Union countries.

Wearable RPM devices maintain the largest market share due to consumer familiarity and continuous technology improvements. Chronic disease monitoring segments (diabetes, cardiovascular, respiratory) are forecast to maintain 20-25% CAGR through 2030 due to increasing disease prevalence and proven cost-effectiveness.

Asia-Pacific represents the highest growth region, with increased disposable incomes, improving healthcare infrastructure, and government manufacturing initiatives creating favorable market conditions for RPM deployment.

What are the biggest barriers that must be solved for mass RPM deployment?

Five fundamental barriers continue to limit RPM's transition from targeted applications to mainstream healthcare deployment, requiring coordinated solutions across technology, regulatory, and payment domains.

Clinical evidence generation remains insufficient for many RPM applications, particularly regarding long-term outcomes and cost-effectiveness across diverse patient populations. Large-scale randomized controlled trials demonstrating improved clinical outcomes and reduced total cost of care are essential for broader payer adoption and physician confidence.

Interoperability standards adoption lags behind technology capabilities, with healthcare systems still struggling to integrate RPM data into existing clinical workflows. Universal FHIR profiles for RPM data and IEEE 11073 device communication standards need widespread implementation to enable seamless multi-vendor environments.

Reimbursement framework inconsistencies create financial uncertainty for healthcare providers considering RPM investments. While Medicare has established five RPM CPT codes, implementation varies across Medicare Administrative Contractors, and private payer policies remain inconsistent.

Patient digital literacy and equitable access represent significant deployment barriers, particularly for elderly patients and underserved communities who would benefit most from RPM services. Solutions require affordable devices, simplified user interfaces, broadband access improvement, and comprehensive patient education programs.

Curious about how money is made in this sector? Explore the most profitable business models in our sleek decks.

Conclusion

Sources

1. A systematic review of the impacts of remote patient monitoring (RPM) interventions on safety, adherence, quality-of-life and cost-related outcomes | npj Digital Medicine
2. Remote Patient Monitoring Market Insights 2024-2029 - Integration of AI in Remote Patient Monitoring
3. What Is Remote Patient Monitoring (RPM)? | Oracle
4. Remote Patient Monitoring Market Growth, Drivers, and Opportunities
5. 8 Remote Patient Monitoring (RPM) Trends for 2025
6. Remote Patient Monitoring Market To Hit USD 88 Billion By 2030 : Wissen Research
7. Remote Patient Monitoring System Market Report, 2030
8. Remote Patient Monitoring in the United States: 2025 Landscape Report
9. A Comprehensive Guide to Remote Patient Monitoring (RPM)
10. Home - BioIntelliSense
11. BioIntelliSense - Crunchbase Company Profile & Funding
12. Remote monitoring startup BioIntelliSense raises $45 million in Series B funding
13. BioIntelliSense - 2025 Company Profile
14. implicity Company Information - Funding, Investors, and More
15. Implicity 2025 Company Profile: Valuation, Funding & Investors
16. AI in Remote Patient Monitoring (RPM) Market worth $8,438.5 million by 2030 with 27.5% CAGR
17. AI in Remote Patient Monitoring (RPM) Market worth $8,438.5 million by 2030 with 27.5% CAGR | The Manila Times
18. Europe Remote Patient Monitoring Systems Market Size & Share Analysis